topotecan has been researched along with bibw 2992 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fu, LW; He, JH; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Ye, S; Zhang, H | 1 |
Fu, LW; Huang, LY; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Yang, K; Ye, S | 1 |
2 other study(ies) available for topotecan and bibw 2992
Article | Year |
---|---|
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; DNA Methylation; Drug Synergism; Humans; Leukemia; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Signal Transduction; Topotecan; Xenograft Model Antitumor Assays | 2014 |
Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Topics: Afatinib; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Neoplasms, Experimental; Quinazolines; Real-Time Polymerase Chain Reaction; Topotecan; Xenograft Model Antitumor Assays | 2014 |